Understanding the molecular intricacies of breast cancer, particularly the HR+/HER2- subtype, is crucial for optimizing therapeutic responses and outcomes, including the potential benefits of immunotherapy, as emphasized in the recent multi-omics study by Jin et al. The gene discussed is ERBB2; the disease is breast carcinoma.